# Impact of Vancomycin Resistance on 30-Day Mortality in Solid Organ Transplant Recipients with Enterococcus faecium Bloodstream Infections: A Retrospective Cohort Analysis

**Authors:** Maria Mazzitelli, Alberto Enrico Maraolo, Umberto Barbieri, Vincenzo Scaglione, Lolita Sasset, Lucrezia Furian, Umberto Cillo, Gino Gerosa, Monica Loy, Emanuele Cozzi, Patrizia Burra, Federico Rea, Annamaria Cattelan

PMC · DOI: 10.3390/antibiotics15020119 · Antibiotics · 2026-01-26

## TL;DR

This study examines whether vancomycin resistance in Enterococcus faecium bloodstream infections affects 30-day mortality in solid organ transplant recipients.

## Contribution

The study clarifies that vancomycin resistance is not an independent predictor of mortality, emphasizing the role of septic shock and supportive care.

## Key findings

- Septic shock was the strongest independent predictor of 30-day mortality in transplant recipients with EF-BSI.
- Vancomycin resistance was not significantly associated with increased mortality in this patient group.
- Source control and early recognition of sepsis were protective or beneficial factors.

## Abstract

Background: Enterococcus faecium bloodstream infections (EF-BSI) cause significant morbidity and mortality in solid organ transplant (SOT) recipients, with the role of vancomycin resistance (VR) remaining controversial as an independent driver. Methods: This was a retrospective cohort study including SOT recipients with EF-BSI at our institution from 2019 to 2023. We used Cox proportional hazards regression to identify predictors of 30-day all-cause mortality. A time-dependent covariate was used to model the effects of receiving targeted, effective antibiotic therapy. Results: A total of 79 patients were included (26.6%, with VR). The overall 30-day mortality was 12.7% (10/79). In univariable analysis, septic shock (Hazard Ratio, HR: 17.1, 95% CI: 3.64–80.8, p < 0.001), the need for Continuous Venovenous Hemofiltration (HR: 6.40, 95% CI: 1.85–22.1, p = 0.003), and a Pitt Bacteremia Score ≥ 2 (HR: 5.17, 95%CI: 1.10–24.3, p = 0.038) were associated with increased mortality, while source control was protective (HR: 0.20, 95% CI: 0.05–0.76, p = 0.018). In the final multivariable model, only septic shock remained an independent predictor of 30-day mortality (HR: 11.4, 95% CI: 1.63–79.5, p = 0.014). VR was not significantly associated with mortality, though the confidence interval was wide and included clinically meaningful effects (HR: 2.07, 95% CI: 0.40–10.6, p = 0.4). Conclusions: In SOT recipients with EF-BSI, 30-day mortality is overwhelmingly driven by the host’s physiological response, manifested as septic shock, rather than the VR profile of the pathogen. The early recognition of severe sepsis/septic shock and the aggressive implementation of supportive care and source control measures in this setting are crucial.

## Linked entities

- **Chemicals:** Vancomycin (PubChem CID 14969)
- **Species:** Enterococcus faecium (taxon 1352)

## Full-text entities

- **Diseases:** diabetes (MESH:D003920), intra-abdominal infection (MESH:D059413), VR (MESH:D060467), VSE (MESH:C562694), liver cirrhosis (MESH:D008103), critically ill (MESH:D016638), shock (MESH:D012769), bacteraemia (MESH:C531821), injury to (MESH:D014947), abscess (MESH:D000038), inflammatory (MESH:D007249), ID (MESH:C537985), cholangitis (MESH:D002761), multi-organ dysfunction (MESH:D009102), acute kidney injury (MESH:D058186), COVID-19 (MESH:D000086382), Bacteremia (MESH:D016470), cardiovascular disease (MESH:D002318), Infections (MESH:D007239), anastomotic leak (MESH:D057868), intra (MESH:D057072), urinary tract infection (MESH:D014552), death (MESH:D003643), septic (MESH:D001170), fungal (MESH:D009181), Septic shock (MESH:D012772), BSIs (MESH:D018805), infectious disease (MESH:D003141), gastrointestinal colonization (MESH:D003108), abdominal infections (MESH:D000007), endocarditis (MESH:D004696)
- **Chemicals:** teicoplanin (MESH:D017334), aminoglycosides (MESH:D000617), Vancomycin (MESH:D014640), linezolid (MESH:D000069349), SOT (-), daptomycin (MESH:D017576), glycopeptide (MESH:D006020)
- **Species:** Escherichia coli (E. coli, species) [taxon 562], Klebsiella (genus) [taxon 570], Human immunodeficiency virus 1 (no rank) [taxon 11676], Homo sapiens (human, species) [taxon 9606], Human immunodeficiency virus (species) [taxon 12721], Enterococcus faecium (species) [taxon 1352]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12937430/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12937430/full.md

## References

32 references — full list in the complete paper: https://tomesphere.com/paper/PMC12937430/full.md

---
Source: https://tomesphere.com/paper/PMC12937430